New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy

HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010
(ots/PRNewswire) -- Today, at the 11th Annual Meeting of the American
Society of Breast Surgeons, Agendia, a world leader in molecular
cancer diagnostics, announced that Breast Cancer Research and
Treatment has published an important study demonstrating the benefit
of adjuvant chemotherapy for patients with a high-risk of breast
cancer recurrence according to the MammaPrint test. The ASBS meeting
takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas,
where you can meet the Agendia team at booth # 314.

The study evaluated 541 patients who were classified as either
high-risk or low-risk for breast cancer recurrence using the 70-gene
MammaPrint signature. For patients classified as high-risk, the
addition of chemotherapy to hormone treatment showed significant
survival benefit and meaningful clinical benefit. This benefit was
not significant in low-risk patients, who were at such reduced risk
for recurrence and cancer-related death, that adding chemotherapy did
not appear to be clinically meaningful.

"It is important to provide patients with individualized
treatment regimens. These findings help further this aim and confirm
MammaPrint's predictive capabilities in determining which patients
are likely to benefit from chemotherapy," commented Richard Bender,
MD, FACP, Chief Medical Officer of Agendia and study co-author.

The study titled, "The predictive value of the 70-gene signature
for adjuvant chemotherapy in early breast cancer," can be accessed at
http://www.springer.com/medicine/oncology/journal/10549.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
under the in vitro diagnostic multivariate index assay (IVDMIA)
guidelines requires clinical and analytical validation and reporting
systems to ensure patient safety issues are addressed. Highly
accurate, MammaPrint identifies patients with early metastasis risk -
patients who are likely to develop metastases within five years
following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear
rationale to assess the benefit of chemotherapy in addition to other
clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited
and CLIA compliant service laboratories. Breast cancer recurrence
assays currently marketed by other manufacturers have not been
subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting-edge
genomics platform for tumor gene expression profiling, the company's
tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical
companies to develop highly effective personalized drugs in the area
of oncology. Agendia is based in Huntington Beach, California, and in
Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: MEDIA CONTACTS: Hans Herklots, Head of Corporate
Communications,Agendia, +31-20-462-1557 Office, +31-620-083-509
Mobile,hans.herklots@agendia.com; Valerie Delva, Account Executive,
RicochetPublic Relations, +1-212-679-3300 x131 Office,
vdelva@ricochetpr.com